Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page’s revision number changed from v3.5.4 to v3.5.5, signaling a minor update to the record.
    Difference
    0.1%
    Check dated 2026-06-05T21:51:55.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.5.3 to v3.5.4. This reflects a minor maintenance update to the page's version history.
    Difference
    0.1%
    Check dated 2026-05-15T14:14:09.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page’s “Revision” label has been updated from v3.5.2 to v3.5.3, indicating a background platform update rather than a change to the trial record content.
    Difference
    0.1%
    Check dated 2026-04-24T05:53:53.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Revision tag updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:29:54.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    Added Revision: v3.5.0. Removed Revision: v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-19T05:20:39.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    Revision tag updated from v3.4.2 to v3.4.3. No study data, eligibility criteria, or location information appears to be affected.
    Difference
    0.1%
    Check dated 2026-03-12T01:03:55.000Z thumbnail image

Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.